IBA’s joint venture PanTera secures EUR 93 million in oversubscribed Series A round to accelerate global actinium-225 production
September 11, 2024 01:00 ET
|
IBA SA
Louvain-la-Neuve, Belgium, September 11, 2024 – IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, is pleased to share the below press release from its joint venture...
IBA publie ses résultats du premier semestre 2024
August 29, 2024 01:00 ET
|
IBA SA
REVENUS DU GROUPE EN HAUSSE DE 21,9% ACCELERATION DE LA CONVERSION DU CARNET DE COMMANDES EN PROTONTHÉRAPIE ET AUTRES ACCELERATEURS FORTE AMELIORATION DE LA MARGE BRUTE ET REBIT À L’EQUILIBRE ...
IBA conclut un accord avec University of Pennsylvania Health System pour deux solutions de protonthérapie Proteus®ONE
August 27, 2024 01:00 ET
|
IBA SA
Un accord dans la continuité du partenariat à long terme entre IBA et University of Pennsylvania Louvain-la-Neuve, Belgique, le 27 août 2024 - IBA (Ion Beam Applications S.A., EURONEXT) le leader...
IBA secures deal with the University of Pennsylvania Health System for two Proteus®ONE proton therapy solutions
August 27, 2024 01:00 ET
|
IBA SA
Agreement further strengthens the long-term relationship between IBA and the University of Pennsylvania Louvain-La-Neuve, Belgium, August 27, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the...
IBA - Regulated Information
August 01, 2024 12:00 ET
|
IBA SA
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, August 1st, 2024 06:00 Summary of the notification IBA (Ion Beam...